Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab impact on coronary microvascular dysfunction in ischemic CAD patients undergoing coronarography
2019-003360-45Phase 2Active
- Sponsor
- CHU Grenoble Alpes
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of evolocumab in atherosclerotic disease, Coronary Small Vessel Disease (CMD) and cardiac ischemia (2 arms), sponsored by CHU Grenoble Alpes. Primary endpoint: Index of microcirculatory resistance (IMR). Started Dec 2019; status: active.
02
Drugs
evolocumab
03
Conditions
atherosclerotic diseaseCoronary Small Vessel Disease (CMD)cardiac ischemia
Beyond the preview
Go deeper on 2019-003360-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003360-45.